Eurofins Scientific SE: Eurofins' Core Business1 Organic Revenue Growth in Q3 2022 Accelerates to Its Mid-Term Objective

Regulatory News: Eurofins Scientific SE (Paris:ERF): Record-high 9M 2022 revenues of €5,033m, +2.7% vs. 9M 2021, driven by steady organic growth and acquisitions that more than compensated

Related Keywords

United States ,United Kingdom ,Ukraine ,America ,Gilles Martin ,Eurofins Genoma ,Firm Net ,European Parliament ,Agency For Care ,Biopharma Contract Development ,Group Core Business ,Contract Research ,Health Of The Flemish Government ,Euronext Paris Stock Exchange ,Eurofins Sustainability Solutions ,Regulatory News ,Food Testing ,North America ,Transplant Genomics ,Trugraf Liver ,Sustainability Solutions ,Join Call ,Growth Calculation ,Half Year ,Nine Months ,Full Year ,Cash Flow ,Core Business ,Consolidated Financial Statements ,Eurofins Scientific ,Eurofins ,Cientific ,More ,Usiness1 ,Rganic ,Revenue ,Growth ,022 ,Ccelerates ,Term ,Objective ,